Equities
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Profile data is unavailable for this security.

About the company

AstraZeneca PLC is a science-led biopharmaceutical company. The Company focuses on the discovery, development, and commercialization of prescription medicines in oncology, rare diseases, and biopharmaceuticals, including cardiovascular, renal & metabolism, and respiratory and immunology. Its pipeline forms a portfolio of investigational therapies in various stages of clinical development and includes the Alexion Rare Disease portfolio comprising approximately 178 projects. Its key marketed oncology products include Tagrisso, Imfinzi, Lynparza, Calquence, Enhertu, Orpathys, Zoladex, Faslodex and others. Its rare diseases products include Soliris, Ultomiris, Strensiq and Kanuma. Its BioPharmaceuticals products include Farxiga, Lokelma, Crestor, Breztri and others. It is also focused on discovering, developing, and manufacturing of T-cell receptor therapies. It also offers investigational vaccine candidate IVX-A12, which targets both respiratory syncytial virus and human metapneumovirus.

  • Revenue in USD (TTM)45.81bn
  • Net income in USD5.96bn
  • Incorporated1992
  • Employees89.90k
  • Location
    AstraZeneca PLC1 Francis Crick AvenueCAMBRIDGE CB2 0AAUnited KingdomGBR
  • Phone+44 207 304 5000
  • Fax+44 207 604 8151
  • Websitehttps://www.astrazeneca.com/
More ▼

Mergers & acquisitions

Acquired companyDeal statusDateDate /
Deal status
AZN:LSE since
announced
Transaction
value
Fusion Pharmaceuticals IncAnnounced19 Mar 202419 Mar 2024Announced3.77%2.30bn
Amolyt Pharma SASAnnounced14 Mar 202414 Mar 2024Announced2.10%1.05bn
Gracell Biotechnologies IncDeal completed26 Dec 202326 Dec 2023Deal completed2.32%1.10bn
Icosavax IncDeal completed12 Dec 202312 Dec 2023Deal completed5.76%862.87m
Data delayed at least 20 minutes, as of Mar 28 2024 18:45 BST.
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.